We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

HOOKIPA Pharma Inc (HOOK) USD0.0001

Sell:$5.91 Buy:$6.43 Change: $0.07 (1.10%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.07 (1.10%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.07 (1.10%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Contact details

350 Fifth Avenue, 72Nd Floor, Suite 7240
United States
+ ()

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$64.22 million
Shares in issue:
12.05 million
United States
US dollar

Key personnel

  • Joern Aldag
    Chief Executive Officer, Director
  • Reinhard Kandera
    Chief Financial Officer, Director
  • Roman Necina
    Chief Operations Officer
  • Klaus Orlinger
    Chief Scientific Officer
  • Mark Winderlich
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.